The purpose of this pharmacological study was to assess the anti-epileptic properties of polyherbal formulations such as Saraswatarishtha Syrup (Baidyanath) (BSS), Epidiolex Oral Solution (Jazz Pharmaceuticals) (JPEOS), and Epifix Capsule (Matsyaveda) (MEC) in rats. JPEOS has one SPM from one medicinal herb, BSS has 230 SPMs from twenty-three medicinal herbs, and Polyherbal Formulations MEC has over 88 SPMs and pharmacotherapeutics from nine medicinal plants and herbs. Additionally, the polyherbal formulations BSS, MEC, and JPEOS had significant TPC content, and the antioxidant potential of each formulation was closely correlated with their TPC concentration. The BSS had a comparatively higher TFC content than MEC and JPEOS. Significant antioxidant activity was seen when the reducing power of the BSS, MEC, and JPEOS formulations increased with dosage. BSS has a reasonably large safety margin and is classified as non-toxic. Animals were pretreated with ployherbal formulations BSS, MEC, and JPEOS for fifteen days before seizures were produced using the MES method, according to in-vivo anti-epileptic action. BSS proved effective in treating epileptic seizures; for example, pre-treatment with BSS formulation dramatically reduced the duration of convulsions and shortened the flexion phase of MES-induced seizures. It was discovered that the ployherbal formulations BSS and MEC were less effective than the common drug Phenytoin, but more effective than lesser dosages. Additionally, both BSS and MEC improved the anti-epiletic effects and reduced the convulsion phase. Comparatively speaking, JPEOS was less successful than BSS and MEC.
Rachna Kumari*, Dr. Bhanu P. S. Sagar, Dr. Amrita Singh (Mon,) studied this question.